Resectable liver cancer
Conditions
Interventions
Experimental group:c-TACE
Sponsors
The First Affiliated Hospital Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. strictly conforms to the standard of clinical diagnosis of the diagnosis and treatment of primary liver cancer (2017 Edition), which is clinically diagnosed as primary liver cancer and received radical resection of liver cancer. 2. patients with primary hepatocellular carcinoma confirmed by histopathology or cytological examination after operation. 3. age: more than 18 years old, not limited to men and women; 4. ECOG score was 0-2 points, and the estimated survival time was 3 months; 5. Child-Pugh liver function rating: A or better B level (less than 7 points); 6. the main organs are functioning normally, that is, they meet the following criteria: (1) blood routine examination: (no blood transfusion, no use of G-CSF, no medication correction) within 14 days before the screening: 1) HB > 90 g/L; 2) WBC > 1.5 x 10^9/L; 3) PLT > 50 x 10^9/L; (2) biochemical examination: (not lost ALB within 14 days); 1) ALT and AST ULN; 3) creatinine was less than 1.5 of ULN; 7. the volunteers voluntarily joined the study, signed informed consent, and had good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women or fertile patients are unwilling or unable to take effective contraceptive measures. 2. Previous or concurrent cases of other untreated malignancies, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and superficial bladder cancer; 3. patients who had previously undergone liver transplantation; 4. patients with HIV infection; 5. patients with incomplete clinical and pathological data before operation; 6. preoperative pathological features of distant metastasis patients; 7. patients receiving other antitumor drugs (including molecular targeted therapy, systemic chemotherapy, etc.); 8. the researchers judged other situations that might affect clinical research and determine the results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 year tumor recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| survival rate; | — |
Countries
China
Contacts
Public ContactJun-hui Sun
The First Affiliated Hospital Zhejiang University
Outcome results
None listed